Stockreport

Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF — First patient in the global Phase 3 program enrolled —— Approximately one in 100 adults and one in 1,000 adolescents in the United States are living with schizophrenia [Read more]